FDA Approves KRISTALOSE — Cumberland Pharmaceuticals Inc.

# FDA Approves Cumberland Pharmaceuticals' KRISTALOSE (Lactulose) for Oral Administration Cumberland Pharmaceuticals Inc. received FDA approval for KRISTALOSE, an oral lactulose formulation, expanding the company's gastrointestinal therapeutic portfolio and positioning it to capture market share in the constipation and hepatic encephalopathy treatment segments. The approval of this generic alternative is expected to enhance Cumberland's competitive positioning in the oral lactulose market while providing healthcare providers and patients with an additional treatment option.